Akoya BioSciences
AKYA
AKYA was delisted on the 7th of July, 2025.
73 hedge funds and large institutions have $135M invested in Akoya BioSciences in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 5 closing their positions.
10,450% more call options, than puts
Call options by funds: $211K | Put options by funds: $2K
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
26% more funds holding
Funds holding: 58 → 73 (+15)
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
0.9% less ownership
Funds ownership: 37.96% → 37.06% (-0.9%)
12% less capital invested
Capital invested by funds: $154M → $135M (-$18.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SW
SVB Wealth
Boston,
Massachusetts
|
+$6.36M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$3.51M |
| 3 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
+$2.86M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.73M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HEC
Hudson Executive Capital
New York
|
-$18.2M |
| 2 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$3.16M |
| 3 |
Millennium Management
New York
|
-$2.65M |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$1.89M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$1.73M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Simplex Trading
Chicago,
Illinois
| – | +$49 | +4 | New |
|
|
BTI
77
Blue Trust Inc
Alpharetta,
Georgia
| – | +$111 | +9 | +31% |
|
AKYA Hedge Fund Activity: Q4 2022 in Review
73 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Akoya BioSciences (AKYA) for Q4 2022, worth a combined $135M — down 12% from $154M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AKYA positions and 5 closed out — a net gain of 15 holders — while 20 added to existing stakes and 20 trimmed.
The largest buyer was SVB Wealth, opening a new position worth an estimated $6.36M. The largest seller was Hudson Executive Capital, cutting an estimated $18.2M.
- 73 institutional investors held Akoya BioSciences (AKYA) as of Q4 2022, up from 58 in Q3 2022.
- Funds reported $135M of Akoya BioSciences stock for Q4 2022, down 12% quarter-over-quarter.
- 20 funds opened new Akoya BioSciences positions in Q4 2022 and 5 closed out, a net change of +15 holders.
- The largest Akoya BioSciences buyer in Q4 2022 was SVB Wealth, an estimated $6.36M added.
- The largest Akoya BioSciences seller in Q4 2022 was Hudson Executive Capital, an estimated $18.2M sold.
Based on aggregated 13F filings for Q4 2022.